In part three of this three-part series, Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what physicians need to know about Molnupiravir as treatment for COVID-19.
Read MoreIn part two of this three-part series, Stephanie Troy, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what to know about Paxlovid as treatment for COVID-19.
Read MoreAMA president Gerald Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 are also discussed.
Guest: John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA
Read MoreAMA CXO Todd Unger is joined by the AMA’s president, Gerald Harmon, MD, a family medicine specialist in Pawleys Island, S.C., who shares new information and big takeaways about therapeutics for COVID-19 after his recent conversation with three physician leaders from the FDA.
Read More
Comentarios recientes